Silence Other Current Assets vs Total Stockholder Equity Analysis
SLN Stock | USD 6.60 0.15 2.33% |
Silence Therapeutics financial indicator trend analysis is much more than just breaking down Silence Therapeutics PLC prevalent accounting drivers to predict future trends. We encourage investors to analyze account correlations over time for multiple indicators to determine whether Silence Therapeutics PLC is a good investment. Please check the relationship between Silence Therapeutics Other Current Assets and its Total Stockholder Equity accounts. Check out World Market Map to better understand how to build diversified portfolios, which includes a position in Silence Therapeutics PLC. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in bureau of economic analysis.
Other Current Assets vs Total Stockholder Equity
Other Current Assets vs Total Stockholder Equity Correlation Analysis
The overlapping area represents the amount of trend that can be explained by analyzing historical patterns of Silence Therapeutics PLC Other Current Assets account and Total Stockholder Equity. At this time, the significance of the direction appears to have significant contrarian relationship.
The correlation between Silence Therapeutics' Other Current Assets and Total Stockholder Equity is -0.26. Overlapping area represents the amount of variation of Other Current Assets that can explain the historical movement of Total Stockholder Equity in the same time period over historical financial statements of Silence Therapeutics PLC, assuming nothing else is changed. The correlation between historical values of Silence Therapeutics' Other Current Assets and Total Stockholder Equity is a relative statistical measure of the degree to which these accounts tend to move together. The correlation coefficient measures the extent to which Other Current Assets of Silence Therapeutics PLC are associated (or correlated) with its Total Stockholder Equity. Values of the correlation coefficient range from -1 to +1, where. The correlation of zero (0) is possible when Total Stockholder Equity has no effect on the direction of Other Current Assets i.e., Silence Therapeutics' Other Current Assets and Total Stockholder Equity go up and down completely randomly.
Correlation Coefficient | -0.26 |
Relationship Direction | Negative |
Relationship Strength | Insignificant |
Other Current Assets
Assets expected to be converted into cash, sold, or consumed either in one year or in the operating cycle, which are not included under standard current asset categories.Total Stockholder Equity
The total equity held by shareholders, calculated as the difference between a company's total assets and total liabilities. It represents the net value of the company owned by shareholders.Most indicators from Silence Therapeutics' fundamental ratios are interrelated and interconnected. However, analyzing fundamental ratios indicators one by one will only give a small insight into Silence Therapeutics PLC current financial condition. On the other hand, looking into the entire matrix of fundamental ratios indicators, and analyzing their relationships over time can provide a more complete picture of the company financial strength now and in the future. Check out World Market Map to better understand how to build diversified portfolios, which includes a position in Silence Therapeutics PLC. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in bureau of economic analysis. At this time, Silence Therapeutics' Selling General Administrative is very stable compared to the past year. As of the 13th of December 2024, Enterprise Value is likely to grow to about 475.5 M, though Tax Provision is likely to grow to (6.7 M).
2021 | 2022 | 2023 | 2024 (projected) | Interest Expense | 8K | 47K | 34K | 32.3K | Depreciation And Amortization | 427K | 482K | 498K | 274.8K |
Silence Therapeutics fundamental ratios Correlations
Click cells to compare fundamentals
Silence Therapeutics Account Relationship Matchups
High Positive Relationship
High Negative Relationship
Silence Therapeutics fundamental ratios Accounts
2019 | 2020 | 2021 | 2022 | 2023 | 2024 (projected) | ||
Total Assets | 46.1M | 86.0M | 96.2M | 107.5M | 93.8M | 98.5M | |
Other Current Liab | 5.1M | 21.8M | 6.2M | 589K | 14.0M | 14.7M | |
Total Current Liabilities | 9.7M | 25.6M | 15.2M | 21.9M | 17.8M | 18.7M | |
Total Stockholder Equity | 20.9M | 9.1M | 8.5M | 22.1M | 17.1M | 20.8M | |
Property Plant And Equipment Net | 611K | 1.1M | 1.9M | 2.2M | 1.8M | 1.9M | |
Net Debt | (13.2M) | (27.1M) | (73.4M) | (54.4M) | (53.8M) | (51.1M) | |
Retained Earnings | (152.0M) | (184.2M) | (223.0M) | (263.3M) | (304.6M) | (289.4M) | |
Accounts Payable | 6.9M | 2.3M | 4.1M | 3.2M | 2.6M | 1.7M | |
Cash | 13.5M | 27.4M | 73.5M | 54.8M | 54.0M | 56.7M | |
Non Current Assets Total | 8.6M | 9.6M | 9.9M | 10.8M | 12.8M | 8.2M | |
Non Currrent Assets Other | 20.0M | (9.6M) | (9.9M) | (10.8M) | 2.6M | 2.7M | |
Cash And Short Term Investments | 33.5M | 37.4M | 73.5M | 71.1M | 54.0M | 56.7M | |
Common Stock Total Equity | 3.5M | 3.6M | 3.9M | 4.2M | 4.8M | 5.0M | |
Common Stock Shares Outstanding | 25.0M | 27.3M | 29.7M | 32.2M | 37.1M | 38.9M | |
Liabilities And Stockholders Equity | 46.1M | 86.0M | 96.2M | 107.5M | 93.8M | 98.5M | |
Non Current Liabilities Total | 15.5M | 51.3M | 72.5M | 63.5M | 59.0M | 62.0M | |
Other Current Assets | 885K | 9.6M | 4.3M | 8.2M | 26.8M | 28.1M | |
Other Stockholder Equity | 171.9M | 153.7M | 184.3M | 226.7M | 251.4M | 264.0M | |
Total Liab | 25.2M | 76.9M | 87.7M | 85.4M | 76.8M | 80.6M | |
Property Plant And Equipment Gross | 611K | 1.1M | 5.5M | 5.5M | 5.6M | 5.8M | |
Total Current Assets | 37.5M | 76.4M | 86.3M | 96.7M | 81.0M | 85.1M | |
Common Stock | 3.9M | 4.2M | 4.5M | 5.4M | 5.9M | 6.2M | |
Accumulated Other Comprehensive Income | 169.0M | 189.1M | 23.8M | 24.3M | 64.3M | 57.1M | |
Net Receivables | 3.1M | 29.3M | 8.5M | 17.3M | 18.8M | 19.8M | |
Good Will | 7.7M | 8.1M | 7.6M | 8.0M | 7.8M | 7.8M | |
Intangible Assets | 34K | 17K | 24K | 320K | 284K | 313.7K | |
Short Term Investments | 319K | 5.0M | 20.0M | 10M | 0.0 | 16.3M | |
Net Tangible Assets | 13.2M | 917K | 910K | 13.7M | 12.4M | 16.7M | |
Property Plant Equipment | 611K | 1.1M | 1.9M | 2.2M | 2.5M | 1.5M | |
Net Invested Capital | 20.9M | 9.1M | 8.5M | 22.1M | 17.1M | 18.9M | |
Net Working Capital | 27.8M | 50.8M | 71.2M | 74.7M | 63.3M | 56.0M | |
Capital Stock | 3.9M | 4.2M | 4.5M | 5.4M | 5.9M | 5.0M |
Pair Trading with Silence Therapeutics
One of the main advantages of trading using pair correlations is that every trade hedges away some risk. Because there are two separate transactions required, even if Silence Therapeutics position performs unexpectedly, the other equity can make up some of the losses. Pair trading also minimizes risk from directional movements in the market. For example, if an entire industry or sector drops because of unexpected headlines, the short position in Silence Therapeutics will appreciate offsetting losses from the drop in the long position's value.Moving together with Silence Stock
Moving against Silence Stock
0.84 | DYAI | Dyadic International | PairCorr |
0.78 | ESPR | Esperion Therapeutics | PairCorr |
0.77 | BMY | Bristol Myers Squibb | PairCorr |
0.57 | GILD | Gilead Sciences | PairCorr |
0.37 | DNA | Ginkgo Bioworks Holdings | PairCorr |
The ability to find closely correlated positions to Silence Therapeutics could be a great tool in your tax-loss harvesting strategies, allowing investors a quick way to find a similar-enough asset to replace Silence Therapeutics when you sell it. If you don't do this, your portfolio allocation will be skewed against your target asset allocation. So, investors can't just sell and buy back Silence Therapeutics - that would be a violation of the tax code under the "wash sale" rule, and this is why you need to find a similar enough asset and use the proceeds from selling Silence Therapeutics PLC to buy it.
The correlation of Silence Therapeutics is a statistical measure of how it moves in relation to other instruments. This measure is expressed in what is known as the correlation coefficient, which ranges between -1 and +1. A perfect positive correlation (i.e., a correlation coefficient of +1) implies that as Silence Therapeutics moves, either up or down, the other security will move in the same direction. Alternatively, perfect negative correlation means that if Silence Therapeutics PLC moves in either direction, the perfectly negatively correlated security will move in the opposite direction. If the correlation is 0, the equities are not correlated; they are entirely random. A correlation greater than 0.8 is generally described as strong, whereas a correlation less than 0.5 is generally considered weak.
Correlation analysis and pair trading evaluation for Silence Therapeutics can also be used as hedging techniques within a particular sector or industry or even over random equities to generate a better risk-adjusted return on your portfolios.Check out World Market Map to better understand how to build diversified portfolios, which includes a position in Silence Therapeutics PLC. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in bureau of economic analysis. You can also try the USA ETFs module to find actively traded Exchange Traded Funds (ETF) in USA.
Is Biotechnology space expected to grow? Or is there an opportunity to expand the business' product line in the future? Factors like these will boost the valuation of Silence Therapeutics. If investors know Silence will grow in the future, the company's valuation will be higher. The financial industry is built on trying to define current growth potential and future valuation accurately. All the valuation information about Silence Therapeutics listed above have to be considered, but the key to understanding future value is determining which factors weigh more heavily than others.
Earnings Share (1.76) | Revenue Per Share 0.429 | Quarterly Revenue Growth (0.93) | Return On Assets (0.22) | Return On Equity (0.64) |
The market value of Silence Therapeutics PLC is measured differently than its book value, which is the value of Silence that is recorded on the company's balance sheet. Investors also form their own opinion of Silence Therapeutics' value that differs from its market value or its book value, called intrinsic value, which is Silence Therapeutics' true underlying value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Because Silence Therapeutics' market value can be influenced by many factors that don't directly affect Silence Therapeutics' underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.
Please note, there is a significant difference between Silence Therapeutics' value and its price as these two are different measures arrived at by different means. Investors typically determine if Silence Therapeutics is a good investment by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, Silence Therapeutics' price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.